HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Frank V Fossella Selected Research

Lung Neoplasms (Lung Cancer)

1/2023Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer.
2/2018Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer.
10/2016The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.
12/2013Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.
4/2005High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Frank V Fossella Research Topics

Disease

43Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
05/2023 - 02/2001
23Neoplasms (Cancer)
08/2023 - 04/2002
7Small Cell Lung Carcinoma (Small Cell Lung Cancer)
02/2014 - 06/2003
6Neutropenia
05/2023 - 04/2002
5Fever (Fevers)
05/2023 - 05/2004
5Lung Neoplasms (Lung Cancer)
01/2023 - 04/2005
4Infections
05/2023 - 07/2002
4Neoplasm Metastasis (Metastasis)
01/2021 - 04/2005
4Diarrhea
10/2019 - 04/2002
3Pneumonia (Pneumonitis)
08/2023 - 01/2018
3Febrile Neutropenia
05/2023 - 07/2002
3Exanthema (Rash)
02/2018 - 04/2002
3Disease Progression
05/2010 - 12/2002
3Vomiting
06/2007 - 04/2002
3Nausea
06/2007 - 04/2002
2Alopecia (Baldness)
05/2023 - 05/2004
2Sepsis (Septicemia)
01/2022 - 02/2018
2Agranulocytosis (Granulocytopenia)
02/2018 - 07/2002
2Esophagitis
01/2009 - 06/2003
2Thrombocytopenia (Thrombopenia)
06/2007 - 04/2002
2Asthenia
12/2005 - 04/2002
2Mucositis
12/2005 - 04/2002
2Carcinoma (Carcinomatosis)
08/2005 - 07/2002
2Mesothelioma
07/2004 - 04/2002
1Respiratory Insufficiency (Respiratory Failure)
01/2022
1Pathologic Complete Response
01/2021
1Hypertension (High Blood Pressure)
10/2019
1Dehydration (Water Stress)
10/2019
1Weight Loss (Weight Reduction)
10/2019
1Malignant Mesothelioma
10/2019
1Hypokalemia
02/2018
1Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome)
02/2018
1Mediastinal Diseases
01/2018
1Hypoxia (Hypoxemia)
12/2013
1Squamous Cell Carcinoma of Head and Neck
12/2011

Drug/Important Bio-Agent (IBA)

12Docetaxel (Taxotere)FDA Link
05/2023 - 02/2001
11Cisplatin (Platino)FDA LinkGeneric
01/2020 - 02/2001
7Pemetrexed (MTA)FDA Link
05/2023 - 04/2002
6Paclitaxel (Taxol)FDA LinkGeneric
05/2010 - 11/2002
6GemcitabineFDA Link
04/2010 - 07/2002
5Carboplatin (JM8)FDA LinkGeneric
05/2010 - 10/2004
4Biomarkers (Surrogate Marker)IBA
10/2016 - 12/2011
4Etoposide (VP 16)FDA LinkGeneric
05/2010 - 06/2003
3NivolumabIBA
01/2023 - 01/2021
3Angiogenesis InhibitorsIBA
10/2019 - 11/2002
3PlatinumIBA
02/2018 - 06/2002
3Taxoids (Taxanes)IBA
12/2011 - 02/2004
3Irinotecan (Camptosar)FDA LinkGeneric
05/2010 - 07/2003
3Vinorelbine (Navelbine)FDA LinkGeneric
04/2010 - 07/2002
2Granulocyte Colony-Stimulating Factor (G-CSF)IBA
05/2023 - 05/2004
2IpilimumabIBA
01/2023 - 01/2021
2HM781-36BIBA
11/2022 - 01/2022
2Erlotinib Hydrochloride (CP 358,774)FDA Link
02/2018 - 10/2016
2Sorafenib (BAY 43-9006)FDA Link
10/2016 - 12/2013
2Imatinib Mesylate (Gleevec)FDA Link
12/2011 - 02/2004
2lonafarnib (SCH 66336)IBA
08/2005 - 05/2004
2taxaneIBA
08/2005 - 05/2004
2Farnesyltranstransferase (Farnesyltransferase)IBA
08/2005 - 05/2004
2MutagensIBA
04/2005 - 04/2005
2Bleomycin (Blenoxane)FDA LinkGeneric
04/2005 - 04/2005
2Amifostine (Ethyol)FDA LinkGeneric
04/2005 - 04/2004
2O-(Chloroacetylcarbamoyl)fumagillol (TNP 470)IBA
10/2004 - 11/2002
11- (1- (imidazo(1,2- a)pyridin- 6- yl)ethyl)- 6- (1- methyl- 1H- pyrazol- 4- yl)- 1H- (1,2,3)triazolo(4,5- b)pyrazineIBA
08/2023
1osimertinibIBA
08/2023
1capmatinibIBA
08/2023
1tepotinibIBA
08/2023
1CrizotinibIBA
08/2023
1pembrolizumabIBA
01/2023
1Tumor Suppressor Proteins (Proteins, Tumor Suppressor)IBA
01/2023
1Proteins (Proteins, Gene)FDA Link
01/2023
1selinexorIBA
01/2023
1trametinibIBA
01/2022
1nintedanibIBA
01/2020
1cediranib (AZD2171)IBA
10/2019
1CobaltIBA
01/2018
1VaccinesIBA
10/2017
1Immune Checkpoint InhibitorsIBA
10/2017
1AZD 6244IBA
10/2016
1MK 2206IBA
10/2016
1lorvotuzumab mertansineIBA
01/2016
1Maytansine (Maitansine)IBA
01/2016
1Immunoconjugates (Immunoconjugate)IBA
01/2016
1Fibroblast Growth Factor 1 (FGF-1)IBA
12/2013
1Tyrosine Kinase InhibitorsIBA
12/2011
1Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
12/2011
1Bevacizumab (Avastin)FDA Link
05/2010
1Filgrastim (Neupogen)FDA Link
04/2010

Therapy/Procedure

23Drug Therapy (Chemotherapy)
05/2023 - 02/2001
18Therapeutics
08/2023 - 12/2002
9Radiotherapy
01/2023 - 04/2002
5Chemoradiotherapy
01/2023 - 01/2004
3Immunotherapy
01/2023 - 07/2016
3Proton Therapy
01/2021 - 01/2018
2Induction Chemotherapy
06/2004 - 01/2004
1Neoadjuvant Therapy
01/2023
1Perioperative Period
02/2018
1Aftercare (After-Treatment)
01/2018
1Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated)
01/2012
1Combination Drug Therapy (Combination Chemotherapy)
04/2010
1Salvage Therapy
04/2010